Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > July 30, 2020
Daily News
July 30, 2020
- Nichi-Iko to Acquire Teva Takeda’s Generic Business
July 30, 2020
- Healios Starts Enrolling COVID-19 Patients in ARDS Cell Therapy Program
July 30, 2020
- Life Science Institute’s Muse Cell Therapy Effective in Epidermolysis Bullosa
July 30, 2020
- Otsuka Files Japan NDA for Preventive Treatment of Migraines
July 30, 2020
- MHLW Finds 57 Suspected Violations in Drug Detailing Activities in FY2019
July 30, 2020
- With Equivocal Honebuto Wording, Off-Year Re-Pricing Debate Delayed Until Year-End
July 30, 2020
- AMED’s Drug Discovery Library under CiCLE Program Ready to Start Operations
July 30, 2020
- AMED Selects 2 Anti-COVID-19 Projects under CiCLE Grant Program
July 30, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…